-- 独立系調査会社CFRAは、に対し、以下の調査速報を提供しました。CFRAのアナリストは、以下のように見解をまとめています。CLXは、2026年度第3四半期の純売上高が前年同期比横ばいの16億7,000万ドル、オーガニック売上高は1%減、調整後EPSは1.64ドルで13%増となり、市場予想を0.10ドル上回りました。製造コストの上昇と不利な製品構成により、売上総利益率は140ベーシスポイント低下し43.2%となりましたが、厳格な経費管理が収益を支えました。セグメント別の業績はまちまちで、家庭用品部門は3%増、国際部門は8%増となった一方、ライフスタイル部門は消費の減少と在庫調整により9%減となりました。経営陣は、2026年度の業績見通しを更新し、純売上高は約6%減、オーガニック売上高は約9%減となる見込みと発表しました。これには、ERP（製品価格調整）による7.5ポイントの逆風が含まれています。 EPSガイダンスは5.45ドル～5.65ドルで、これは27%～29%の減少に相当し、GOJOの在庫評価増とエネルギーコストの上昇により、粗利益率は250～300ベーシスポイント縮小すると予想されます。4月1日のGOJO買収によりヘルスケア事業ポートフォリオは拡大しますが、短期的な統合コストが業績を圧迫します。当社は、完了した5億8,000万ドルのデジタル変革により、マクロ経済の逆風にもかかわらず、CLXは長期的な事業改善に向けて有利な立場に立つことができると考えています。
Related Articles
Research
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
$HLT
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
$UHS
Asia
Briscoe Group Fiscal Q1 Sales Tick Higher
Briscoe Group (NZE:BGP, ASX:BGP) said its sales for the fiscal first quarter ended April 26 increased over 1% year over year to NZ$180.8 million, according to Friday filings with the Australian and New Zealand bourses.Sales in the company's homeware segment rose 2% to NZ$105.7 million, and sporting goods sales edged 0.5% higher to NZ$75.1 million.The company said discretionary consumer spending has dampened due to the Middle East conflict, with a noticeable impact on the retail sector during the latter part of the quarter, while bad weather in New Zealand also had a negative impact on store traffic.
$ASX:BGP$NZE:BGP